Home » Merck’s Keytruda Shows Positive Results for Treating Blood Cancer
Merck’s Keytruda Shows Positive Results for Treating Blood Cancer
Merck’s Keytruda saw more wins last week as the firm unveiled data supporting its possible benefits across a range of blood cancers, including multiple myeloma for the first time, as well as Hodgkin lymphoma, B-cell lymphoma and chronic lymphocytic leukemia.
A PD-1 inhibitor, Keytruda (pembrolizumab) already has bagged approval for advanced melanoma and non-small cell lung cancer — and most recently breakthrough therapy designation for metastatic colorectal cancer. Even without the new potential indications, an analyst has estimated the treatment could bring in up to $5 billion for Merck in 2020.
Upcoming Events
-
21Oct